- Drug: Nivestym (filgrastim-aafi)
- Manufacturer: Pfizer
Route of Administration: Subcutaneous
- Site of Care: Outpatient
Approved Indication:
-
- to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
- to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
-
Disease: neutropenia associated with myelosuppressive anti-cancer therapy, hematopoietic stem cell transplantation, cyclic/congenital/idiopathic neutropenia
Therapeutic Area: Hematology, Oncology
- Enrollment Form Link: Financial Assistance
- Phone Number: 1-877-744-5675
- Fax Number: N/A
- Product Website: nivestym.com